Business Description
ISIN : US4330001060
Share Class Description:
HIMS: Ordinary Shares - Class ATotal Employee Number:
2,442Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.54 | |||||
Equity-to-Asset | 0.09 | |||||
Debt-to-Equity | 4.77 | |||||
Debt-to-EBITDA | -22.97 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 1.59 | |||||
Beneish M-Score | 37.39 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 52.2 | |||||
3-Year Book Growth Rate | 16.7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 24.17 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 33.62 | |||||
9-Day RSI | 40.39 | |||||
14-Day RSI | 43.34 | |||||
3-1 Month Momentum % | 14.82 | |||||
6-1 Month Momentum % | 95.5 | |||||
12-1 Month Momentum % | -33.15 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.93 | |||||
Quick Ratio | 0.87 | |||||
Cash Ratio | 0.57 | |||||
Days Inventory | 44.37 | |||||
Days Sales Outstanding | 17.13 | |||||
Days Payable | 112.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.9 | |||||
Shareholder Yield % | -14.64 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 68.43 | |||||
Operating Margin % | -5.99 | |||||
Net Margin % | -5.51 | |||||
EBITDA Margin % | -2.61 | |||||
FCF Margin % | 2.39 | |||||
OCF Margin % | 10.22 | |||||
ROE % | -28.93 | |||||
ROA % | -5.84 | |||||
ROIC % | -8.84 | |||||
3-Year ROIIC % | 12.72 | |||||
ROC (Joel Greenblatt) % | -36.09 | |||||
ROCE % | -8.65 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 46.65 | |||||
PS Ratio | 2.6 | |||||
PB Ratio | 19.95 | |||||
Price-to-Free-Cash-Flow | 112.19 | |||||
Price-to-Operating-Cash-Flow | 26.04 | |||||
EV-to-EBIT | -46.4 | |||||
EV-to-Forward-EBIT | 78.49 | |||||
EV-to-EBITDA | -106.49 | |||||
EV-to-Forward-EBITDA | 39.92 | |||||
EV-to-Revenue | 2.78 | |||||
EV-to-Forward-Revenue | 1.92 | |||||
EV-to-FCF | 116.34 | |||||
Price-to-GF-Value | 0.63 | |||||
Price-to-Projected-FCF | 8.37 | |||||
Earnings Yield (Greenblatt) % | -2.16 | |||||
FCF Yield % | 0.95 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:HIMS
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Hims & Hers Health Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2,578.112 | ||
| EPS (TTM) ($) | -0.63 | ||
| Beta | 4.0603 | ||
| 3-Year Sharpe Ratio | 0.91 | ||
| 3-Year Sortino Ratio | 1.86 | ||
| Volatility % | 97.83 | ||
| 14-Day RSI | 43.34 | ||
| 14-Day ATR ($) | 2.04126 | ||
| 20-Day SMA ($) | 29.8645 | ||
| 12-1 Month Momentum % | -33.15 | ||
| 52-Week Range ($) | 13.74 - 65.2994 | ||
| Shares Outstanding (Mil) | 233.31 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hims & Hers Health Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Hims & Hers Health Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-23 17:00 | In 170 days | ||
| Annual report for 2026 | 2027-02-23 | In 169 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-23 | In 169 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-03 17:00 | In 58 days | ||
| Third quarter earnings results for 2026 | 2026-11-03 | In 57 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-10 17:00 | 31.59 (+4.64%) | ||
| Second quarter earnings results for 2026 | 2026-08-10 | 31.59 (+4.64%) | ||
| General meeting for 2026 | 2026-06-11 11:00 | 27.78 (-2.11%) | ||
| First quarter earnings conference call for 2026 | 2026-05-11 17:00 | 28.27 (+10.39%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 28.27 (+10.39%) |
Hims & Hers Health Inc Frequently Asked Questions
Guru Commentaries on NYSE:HIMS
Our history with HIMS extends to 2021. More recently, we maintained a cautious view because of the company’s reliance on compounded GLP-1 medications, concerns regarding prescribing and compliance practices, the termination of its initial partnership with Novo Nordisk (NVO), and Novo’s subsequent patent-infringement litigation. We also held a long position throughout 2024 based on our broader conviction in the long-term adoption of telehealth. Following the company’s Q1 results and what we viewed as reduced uncertainty around compounded GLP-1 products, we initiated a new long position. HIMS ended the quarter as the strategy’s second-largest holding.
Our position in Hims & Hers, Inc. (HIMS) contributed to performance. The stock rose following strong 1Q25 earnings driven by an increase in subscriber growth and growing net income. The machine learning models maintained a positive view, largely driven by its quality features and in particular its return on invested capital (ROIC), return on equity (ROE), and capital acquisition ratio.
Our position in Hims & Hers, Inc. (HIMS) was a positive contributor to performance. The stock gained early in the quarter, driven by macro tailwinds from the new administration and the success of its Super Bowl ad. Despite challenges, including tariffs out of China and Mexico, and growing competition concerns, the models retained their conviction in the stock at year-end. Throughout this volatility, the machine learning models actively managed the position taking profits on strength and buying on weakness enhancing relative performance.
Press Release
Articles on Hims & Hers Health Inc
Headlines
See More- 1
- 1
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
